Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy

Despite advancements in cancer therapeutics, acute myeloid leukemia patients over 60 years old have a 5-year survival rate of less than 8%. In an attempt to improve this, epigenetic modifying agents have been combined as therapies in clinical studies. In particular combinations with Decitabine and V...

Descripción completa

Detalles Bibliográficos
Autores principales: Young, Christine S., Clarke, Kathryn M., Kettyle, Laura M., Thompson, Alexander, Mills, Ken I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584259/
https://www.ncbi.nlm.nih.gov/pubmed/28881658
http://dx.doi.org/10.18632/oncotarget.18009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584259/
https://www.ncbi.nlm.nih.gov/pubmed/28881658
http://dx.doi.org/10.18632/oncotarget.18009

Ejemplares similares